Dr. Shore Discusses Hormonal Therapy In Prostate Cancer For Learning Clinicians

/0 Comments/in /by

Dr. Shore, an expert in urologic oncology, discusses hormonal therapy in prostate cancer. He leads an educational discussion and course on prostate cancer for learning clinicians. The activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, and other professionals involved in the management of patients with prostate cancer. 

For clinicians to access the course use the link below to access the course and begin the pre-test. In order to receive CME credit, participants must view the activity and complete the post-test and evaluation form. 

Click here to take the course and watch the discussion

 

 

 

Dr. Shore & Colleagues Host A 4-Part Interactive Webinar Series For Learning Clinicians

/0 Comments/in /by

Key Issues For The Advanced Bladder Cancer Clinic: Incorporating Immunotherapy Into Your Community-Based Urology Practice

Join Dr. Neal Shore and his esteemed colleagues for this four-part webinar series focused on the implementation of IO, as well as other recently approved advanced bladder cancer therapies. This series was designed for all clinicians interested in bladder cancer treatment, but especially for those dedicated community urology practices desiring to establish an advanced bladder cancer clinic of excellence. 
Earn 1.0 Credit hours (ACCME/ACPE/ANCC) for each webinar.

For clinicians, to view the interactive webinars, click the link below and choose which webinar you would like to begin. Then log in or register to gain access and begin the course.

Click here to access the interactive webinars

Dr. Shore’s article chosen as a NEJM “Most Notable Articles of 2020”

/0 Comments/in /by

Neal Shore, MD, Article Featured in Notable Articles of 2020 by The New England Journal of Medicine.

The New England Journal of Medicine editors have selected Dr. Shore’s article Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer to be featured in Notable Articles of 2020. This is a selection of articles that have been the most meaningful in changing medical practice and improving patient care in 2020.

 

To access this article please click the link below for The New England Journal of Medicine’s website and create a free log-in. Once logged into your account, the collection will be accessible under the “Special Offers” tab.

Click here for the New England Journal of Medicine’s website.

Neal Shore, MD, FACS: Relugolix Approval for Advanced Prostate Cancer

/0 Comments/in /by

Interview with Neal Shore, MD, FACS, about the approval of Relugolix for advanced prostate cancer and the significance of the treatment.

Click here to read more.

Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results

/0 Comments/in /by

Neal Shore, Steven A. Kaplan, Ronald Tutrone, Richard Levin, James Bailen, Alan Hay, Susan Kalota, Mohamed Bidair, Sheldon Freedman, Kenneth Goldberg, Frederick Snoy & Jonathan I. Epstein

Click here to read more.

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

/0 Comments/in /by

Prof Stephen A Boorjian, MD, Mehrdad Alemozaffar, MD, Prof Badrinath R Konety, MD, Neal D Shore, MD, Prof Leonard G Gomella, MD, Prof Ashish M Kamat, MD, et al.

Background: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer.

Click here to read more.

Resetting the Bar of Castration Resistance – Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer

/0 Comments/in /by

Neal D. Shore, Alicia K. Morgans, Charles J. Ryan

Click here to read more.

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

/0 Comments/in /by

Maha Hussain, M.D., Joaquin Mateo, M.D., Karim Fizazi, M.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Antoine Thiery-Vuillemin, M.D., Przemyslaw Twardowski, M.D., et al., for the PROfound Trial Investigators*

Click here to read more.

Interview with Dr. Neal Shore Featured on WCSC Live 5 News

/0 Comments/in /by

Prostate cancer treatment interview with Dr. Neal Shore featured on WCSC Live 5 News

Click on the video below to watch the interview: